Home -> Law Blog Directory -> Patent Law Blogs -> Patent Docs

Patent Law

: Patent Docs

ALZA Corp. v. Andrx Pharmaceuticals, LLC (Fed. Cir. 2010)

By Donald Zuhn, Kevin Noonan, Chris Singer, Sherri Oslick, and Jason Derry

By Andrew Williams -- Last week, in ALZA Corp. v. Andrx Pharms., LLC, the Federal Circuit affirmed the U.S. District Court for the District of Delaware's decision that ALZA's patent related to treating Attention Deficit and Hyperactivity Disorder ("ADHD") was invalid for lack of enablement. ALZA markets the drug Concerta® for the treatment of ADHD, which releases methylphenidate after ingestion at an ascending rate over an extended period of time. Methylphenidate is the same active ingredient as found in Ritalin®. However, because Ritalin® is an immediate-release formulation, it had to be administered two to three times a day. And, as...

Full post as published by Patent Docs on May 04, 2010 (boomark / email).